logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn moving towards Phase 2 trial to treat NASH with flagship leronlimab drug

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech has filed an Investigational New Drug (IND) application and a Phase 2 clinical trial protocol with the FDA for its flagship drug leronlimab to treat patients with non-alcoholic steatohepatitis (NASH).

Pourhassan says because the company has positive pre-clinical data, with zero-drug related adverse effects, the company can file to skip Phase 1 and go straight to Phase 2.

Quick facts: CytoDyn Inc.

Price: 3.8535 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan says its drug leronlimab showed early clinical improvement in mild-to-moderate coronavirus patients in a recently completed Phase 2 trial. Pourhassan says in patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating...

2 days, 3 hours ago

2 min read